US 11,883,164 B2
System and methods for processing analyte sensor data for sensor calibration
Apurv U Kamath, San Diego, CA (US); Jack Pryor, San Diego, CA (US); Paul V. Goode, Jr., Round Rock, TX (US); James H Brauker, Addison, MI (US); and Aarthi Mahalingam, San Diego, CA (US)
Assigned to Dexcom, Inc., San Diego, CA (US)
Filed by Dexcom, Inc., San Diego, CA (US)
Filed on Jan. 12, 2022, as Appl. No. 17/574,447.
Application 17/574,447 is a continuation of application No. 17/076,714, filed on Oct. 21, 2020, abandoned.
Application 17/076,714 is a continuation of application No. 16/983,885, filed on Aug. 3, 2020, abandoned.
Application 16/983,885 is a continuation of application No. 16/691,107, filed on Nov. 21, 2019, granted, now 10,898,114.
Application 16/691,107 is a continuation of application No. 16/457,628, filed on Jun. 28, 2019, granted, now 10,610,136.
Application 16/457,628 is a continuation of application No. 15/787,595, filed on Oct. 18, 2017, abandoned.
Application 15/787,595 is a continuation of application No. 15/065,623, filed on Mar. 9, 2016, granted, now 9,918,668.
Application 15/065,623 is a continuation of application No. 13/607,162, filed on Sep. 7, 2012, granted, now 9,314,196.
Application 13/607,162 is a continuation of application No. 12/683,755, filed on Jan. 7, 2010, granted, now 8,611,978.
Application 12/683,755 is a continuation of application No. 11/373,628, filed on Mar. 9, 2006, granted, now 7,920,906.
Claims priority of provisional application 60/660,743, filed on Mar. 10, 2005.
Prior Publication US 2022/0125355 A1, Apr. 28, 2022
Int. Cl. A61B 5/1486 (2006.01); A61B 5/1473 (2006.01); A61B 5/1495 (2006.01); A61B 5/05 (2021.01); A61B 5/1468 (2006.01); A61B 5/145 (2006.01); A61B 5/00 (2006.01); A61B 5/15 (2006.01); A61B 17/34 (2006.01); A61M 5/172 (2006.01); A61M 5/158 (2006.01); A61M 5/142 (2006.01)
CPC A61B 5/14532 (2013.01) [A61B 5/0002 (2013.01); A61B 5/0004 (2013.01); A61B 5/0031 (2013.01); A61B 5/05 (2013.01); A61B 5/1411 (2013.01); A61B 5/1451 (2013.01); A61B 5/1473 (2013.01); A61B 5/1486 (2013.01); A61B 5/1495 (2013.01); A61B 5/14503 (2013.01); A61B 5/14507 (2013.01); A61B 5/14514 (2013.01); A61B 5/14546 (2013.01); A61B 5/14735 (2013.01); A61B 5/14865 (2013.01); A61B 5/6801 (2013.01); A61B 5/6833 (2013.01); A61B 5/6848 (2013.01); A61B 5/6849 (2013.01); A61B 5/68335 (2017.08); A61B 5/72 (2013.01); A61B 17/3468 (2013.01); A61B 5/14 (2013.01); A61B 5/145 (2013.01); A61B 5/1468 (2013.01); A61B 5/150022 (2013.01); A61B 2017/3492 (2013.01); A61B 2560/0223 (2013.01); A61B 2560/045 (2013.01); A61B 2560/063 (2013.01); A61B 2562/18 (2013.01); A61M 5/14244 (2013.01); A61M 5/1723 (2013.01); A61M 2005/1585 (2013.01); Y02A 90/10 (2018.01)] 39 Claims
OG exemplary drawing
 
1. A glucose monitoring system comprising:
a transcutaneous electrochemical glucose sensor comprising:
an in vivo portion configured to be inserted into a body of a human host, the in vivo portion having at least one electrode and a membrane containing glucose oxidase; and
an ex vivo portion configured to remain outside of the body of the host; and
at least one processor programmed to:
calculate an in vivo sensitivity for the transcutaneous electrochemical glucose sensor by converting an in vitro sensitivity associated with the transcutaneous electrochemical glucose sensor, wherein the in vitro sensitivity is obtained prior to insertion of the transcutaneous electrochemical glucose sensor, wherein the in vitro sensitivity is different from the in vivo sensitivity; and
determine an estimated glucose value based on an in vivo measurement from the in vivo portion of the transcutaneous electrochemical glucose sensor and the calculated in vivo sensitivity for the transcutaneous electrochemical glucose sensor,
wherein the in vivo sensitivity for the transcutaneous electrochemical glucose sensor is calculated without a need for a reference analyte measurement obtained after insertion of the in vivo portion of the transcutaneous electrochemical glucose sensor into the body of the human host.